サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1402925

術後悪心・嘔吐（PONV）市場：世界の業界分析、規模、シェア、成長、動向、予測、2023～2031年

Post-operative Nausea and Vomiting Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

出版日
ページ情報
英文 166 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.87円
術後悪心・嘔吐（PONV）市場：世界の業界分析、規模、シェア、成長、動向、予測、2023～2031年
出版日: 2023年11月30日
発行: Transparency Market Research
ページ情報: 英文 166 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

術後悪心・嘔吐（PONV）市場- レポートの範囲

世界の術後悪心・嘔吐（PONV）市場に関するTMRのレポートは、過去と現在の成長動向、および2023年から2031年の予測期間中に市場の指標の貴重な洞察を得る機会を研究しています。レポートは収益を提供します。 2023年を基準年、2031年を予測年として考慮した、2017年から2031年の期間の世界の術後悪心・嘔吐（PONV）市場。レポートは、2023年から2031年までの世界の術後悪心・嘔吐（PONV）市場の複合年間成長率（CAGR％）も提供します。

このレポートは広範な調査を経て作成されました。1次調査では、調査活動の大部分が行われ、アナリストが主要なオピニオンリーダー、業界リーダー、オピニオンメーカーにインタビューを実施しました。2次調査には、術後悪心・嘔吐（PONV）市場を理解するために、主要企業の製品文献、年次報告書、プレスリリース、および関連文書の参照が含まれます。

市場スナップショット
2023年の市場価値 21億米ドル
2031年の市場価値 40億米ドル
CAGR 7.4%

このレポートは、世界の術後悪心・嘔吐（PONV）市場の競合情勢を詳しく掘り下げています。世界の術後悪心・嘔吐（PONV）市場で活動する主要企業が特定され、これらのそれぞれがさまざまな属性の観点からプロファイルされています。会社概要、財務状況、最近の動向、 SWOTは、このレポートで紹介されている世界の術後悪心・嘔吐（PONV）市場のプレーヤーの属性です。

目次

第1章 エグゼクティブサマリー

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

  • 市場セグメンテーション
  • 概要
  • 市場力学
  • 世界市場の分析と予測、2022～2031年

第5章 重要な洞察

  • パイプライン分析
  • COVID-19パンデミックが業界に与える影響

第6章 市場分析と予測：治療タイプ別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：治療タイプ別、2023-2031
    • セロトニン拮抗薬
    • ステロイド
    • ドーパミン拮抗薬
    • NK-1受容体拮抗薬
    • 非薬物治療
    • その他
  • 市場の魅力：治療タイプ別

第7章 世界市場の分析と予測：流通チャネル別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：流通チャネル別、2023-2031
    • 病院薬局
    • オンライン薬局
    • 小売薬局・ドラッグストア
  • 市場の魅力：流通チャネル別

第8章 世界市場の分析と予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別、2023-2031
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場の魅力：地域別

第9章 北米市場の分析と予測

第10章 欧州市場の分析と予測

第11章 アジア太平洋市場の分析と予測

第12章 ラテンアメリカ市場の分析と予測

第13章 中東・アフリカ市場の分析と予測

第14章 競合情勢

  • 市場プレーヤー-競合マトリックス（企業の階層および規模別）
  • 市場シェア分析：企業別（2022年）
  • 企業プロファイル
    • Acacia Pharma
    • F. Hoffmann-La Roche AG
    • Novartis AG
    • Ani Pharmaceuticals, Inc.
    • Camurus AB
    • Sanofi SA
    • Helsinn Holding SA
    • Eisai Corporation
    • GlaxoSmithKline Corporation
    • Merck and Co.
図表

List of Tables

  • Table 01: Global Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Treatment Type, 2023-2031
  • Table 02: Global Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Distribution Channel, 2023-2031
  • Table 03: Global Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Region, 2023-2031
  • Table 04: North America Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Treatment Type, 2023-2031
  • Table 05: North America Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Distribution Channel, 2023-2031
  • Table 06: North America Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Country, 2023-2031
  • Table 07: Europe Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Treatment Type, 2023-2031
  • Table 08: Europe Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Distribution Channel, 2023-2031
  • Table 09: Europe Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023-2031
  • Table 10: Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Treatment Type, 2023-2031
  • Table 11: Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Distribution Channel, 2023-2031
  • Table 12: Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023-2031
  • Table 13: Latin America Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Treatment Type, 2023-2031
  • Table 14: Latin America Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Distribution Channel, 2023-2031
  • Table 15: Latin America Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023-2031
  • Table 16: Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Treatment Type, 2023-2031
  • Table 17: Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Distribution Channel, 2023-2031
  • Table 18: Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023-2031

List of Figures

  • Figure 01: Global Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, 2023-2031
  • Figure 02: Global Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Treatment Type, 2022 and 2031
  • Figure 03: Global Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Treatment Type, 2023-2031
  • Figure 04: Global Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 05: Global Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 06: Global Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 07: Global Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 08: North America Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, 2023-2031
  • Figure 09: North America Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Treatment Type, 2022 and 2031
  • Figure 10: North America Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Treatment Type, 2023-2031
  • Figure 11: North America Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 12: North America Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 13: North America Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 14: North America Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 15: Europe Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, 2023-2031
  • Figure 16: Europe Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Treatment Type, 2022 and 2031
  • Figure 17: Europe Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Treatment Type, 2023-2031
  • Figure 18: Europe Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 19: Europe Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 20: Europe Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 21: Europe Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 22: Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, 2023-2031
  • Figure 23: Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Treatment Type, 2022 and 2031
  • Figure 24: Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Treatment Type, 2023-2031
  • Figure 25: Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 26: Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 27: Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 28: Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 29: Latin America Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, 2023-2031
  • Figure 30: Latin America Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Treatment Type, 2022 and 2031
  • Figure 31: Latin America Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Treatment Type, 2023-2031
  • Figure 32: Latin America Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 33: Latin America Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 34: Latin America Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 35: Latin America Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 36: Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, 2023-2031
  • Figure 37: Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Treatment Type, 2022 and 2031
  • Figure 38: Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Treatment Type, 2023-2031
  • Figure 39: Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 40: Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 41: Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 42: Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 43: Global Post-operative Nausea and Vomiting (PONV) Market Share Analysis, by Company, 2022
目次
Product Code: TMRGL2969

Post-operative Nausea and Vomiting (PONV) Market - Scope of Report

TMR's report on the global post-operative nausea and vomiting (PONV) market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global post-operative nausea and vomiting (PONV) market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global post-operative nausea and vomiting (PONV) market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the post-operative nausea and vomiting (PONV) market.

Market Snapshot
Market Value in 2023US$ 2.1 Bn
Market Value in 2031US$ 4 Bn
CAGR7.4%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global post-operative nausea and vomiting (PONV) market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global post-operative nausea and vomiting (PONV) market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global post-operative nausea and vomiting (PONV) market.

The report delves into the competitive landscape of the global post-operative nausea and vomiting (PONV) market. Key players operating in the global post-operative nausea and vomiting (PONV) market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global post-operative nausea and vomiting (PONV) market profiled in this report.

Key Questions Answered in Global post-operative nausea and vomiting (PONV) Market Report:

  • What is the sales/revenue generated by post-operative nausea and vomiting (PONV) across all regions during the forecast period?
  • What are the opportunities in the global post-operative nausea and vomiting (PONV) market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Post-operative Nausea and Vomiting (PONV) Market - Research Objectives and Research Approach

The comprehensive report on the global post-operative nausea and vomiting (PONV) market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global post-operative nausea and vomiting (PONV) market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global post-operative nausea and vomiting (PONV) market.

Table of Contents

1. Executive Summary

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Post-operative Nausea and Vomiting (PONV) Market

4. Market Overview

  • 4.1. Market Segmentation
    • 4.1.1. Segment Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast, 2022-2031

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. COVID-19 Pandemic Impact on Industry

6. Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast, by Treatment Type

  • 6.1. Introduction and Definitions
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Treatment Type, 2023-2031
    • 6.3.1. Serotonin Antagonists
    • 6.3.2. Steroids
    • 6.3.3. Dopamine Antagonists
    • 6.3.4. NK-1 Receptor Antagonists
    • 6.3.5. Non-pharmacologic Treatment
    • 6.3.6. Others
  • 6.4. Market Attractiveness, by Treatment Type

7. Global Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast, by Distribution Channel

  • 7.1. Introduction and Definitions
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Distribution Channel, 2023-2031
    • 7.3.1. Hospital Pharmacies
    • 7.3.2. Online Pharmacies
    • 7.3.3. Retail Pharmacies & Drug Stores
  • 7.4. Market Attractiveness, by Distribution Channel

8. Global Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast, by Region

  • 8.1. Key Findings
  • 8.2. Market Value Forecast, by Region, 2023-2031
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3. Market Attractiveness, by Region

9. North America Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast

  • 9.1. Introduction
    • 9.1.1. Key Findings
  • 9.2. Market Value Forecast, by Treatment Type, 2023-2031
    • 9.2.1. Serotonin Antagonists
    • 9.2.2. Steroids
    • 9.2.3. Dopamine Antagonists
    • 9.2.4. NK-1 Receptor Antagonists
    • 9.2.5. Non-pharmacologic Treatment
    • 9.2.6. Others
  • 9.3. Market Value Forecast, by Distribution Channel, 2023-2031
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Online Pharmacies
    • 9.3.3. Retail Pharmacies & Drug Stores
  • 9.4. Market Value Forecast, by Country, 2023-2031
    • 9.4.1. U.S.
    • 9.4.2. Canada
  • 9.5. Market Attractiveness Analysis
    • 9.5.1. By Treatment Type
    • 9.5.2. By Distribution Channel
    • 9.5.3. By Country

10. Europe Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Treatment Type, 2023-2031
    • 10.2.1. Serotonin Antagonists
    • 10.2.2. Steroids
    • 10.2.3. Dopamine Antagonists
    • 10.2.4. NK-1 Receptor Antagonists
    • 10.2.5. Non-pharmacologic Treatment
    • 10.2.6. Others
  • 10.3. Market Value Forecast, by Distribution Channel, 2023-2031
    • 10.3.1. Hospital Pharmacies
    • 10.3.2. Online Pharmacies
    • 10.3.3. Retail Pharmacies & Drug Stores
  • 10.4. Market Value Forecast, by Country/Sub-region, 2023-2031
    • 10.4.1. Germany
    • 10.4.2. U.K.
    • 10.4.3. France
    • 10.4.4. Italy
    • 10.4.5. Spain
    • 10.4.6. Rest of Europe
  • 10.5. Market Attractiveness Analysis
    • 10.5.1. By Treatment Type
    • 10.5.2. By Distribution Channel
    • 10.5.3. By Country/Sub-region

11. Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Treatment Type, 2023-2031
    • 11.2.1. Serotonin Antagonists
    • 11.2.2. Steroids
    • 11.2.3. Dopamine Antagonists
    • 11.2.4. NK-1 Receptor Antagonists
    • 11.2.5. Non-pharmacologic Treatment
    • 11.2.6. Others
  • 11.3. Market Value Forecast, by Distribution Channel, 2023-2031
    • 11.3.1. Hospital Pharmacies
    • 11.3.2. Online Pharmacies
    • 11.3.3. Retail Pharmacies & Drug Stores
  • 11.4. Market Value Forecast, by Country/Sub-region, 2023-2031
    • 11.4.1. China
    • 11.4.2. Japan
    • 11.4.3. India
    • 11.4.4. Australia & New Zealand
    • 11.4.5. Rest of Asia Pacific
  • 11.5. Market Attractiveness Analysis
    • 11.5.1. By Treatment Type
    • 11.5.2. By Distribution Channel
    • 11.5.3. By Country/Sub-region

12. Latin America Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Treatment Type, 2023-2031
    • 12.2.1. Serotonin Antagonists
    • 12.2.2. Steroids
    • 12.2.3. Dopamine Antagonists
    • 12.2.4. NK-1 Receptor Antagonists
    • 12.2.5. Non-pharmacologic Treatment
    • 12.2.6. Others
  • 12.3. Market Value Forecast, by Distribution Channel, 2023-2031
    • 12.3.1. Hospital Pharmacies
    • 12.3.2. Online Pharmacies
    • 12.3.3. Retail Pharmacies & Drug Stores
  • 12.4. Market Value Forecast, by Country/Sub-region, 2023-2031
    • 12.4.1. Brazil
    • 12.4.2. Mexico
    • 12.4.3. Rest of Latin America
  • 12.5. Market Attractiveness Analysis
    • 12.5.1. By Treatment Type
    • 12.5.2. By Distribution Channel
    • 12.5.3. By Country/Sub-region

13. Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Treatment Type, 2023-2031
    • 13.2.1. Serotonin Antagonists
    • 13.2.2. Steroids
    • 13.2.3. Dopamine Antagonists
    • 13.2.4. NK-1 Receptor Antagonists
    • 13.2.5. Non-pharmacologic Treatment
    • 13.2.6. Others
  • 13.3. Market Value Forecast, by Distribution Channel, 2023-2031
    • 13.3.1. Hospital Pharmacies
    • 13.3.2. Online Pharmacies
    • 13.3.3. Retail Pharmacies & Drug Stores
  • 13.4. Market Value Forecast, by Country/Sub-region, 2023-2031
    • 13.4.1. GCC Countries
    • 13.4.2. South Africa
    • 13.4.3. Rest of Middle East & Africa
  • 13.5. Market Attractiveness Analysis
    • 13.5.1. By Treatment Type
    • 13.5.2. By Distribution Channel
    • 13.5.3. By Country/Sub-region

14. Competition Landscape

  • 14.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 14.2. Market Share Analysis, by Company (2022)
  • 14.3. Company Profiles
    • 14.3.1. Acacia Pharma
      • 14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.1.2. Product Portfolio
      • 14.3.1.3. Financial Overview
      • 14.3.1.4. SWOT Analysis
      • 14.3.1.5. Strategic Overview
    • 14.3.2. F. Hoffmann-La Roche AG
      • 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.2.2. Product Portfolio
      • 14.3.2.3. Financial Overview
      • 14.3.2.4. SWOT Analysis
      • 14.3.2.5. Strategic Overview
    • 14.3.3. Novartis AG
      • 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.3.2. Product Portfolio
      • 14.3.3.3. Financial Overview
      • 14.3.3.4. SWOT Analysis
      • 14.3.3.5. Strategic Overview
    • 14.3.4. Ani Pharmaceuticals, Inc.
      • 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.4.2. Product Portfolio
      • 14.3.4.3. Financial Overview
      • 14.3.4.4. SWOT Analysis
      • 14.3.4.5. Strategic Overview
    • 14.3.5. Camurus AB
      • 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.5.2. Product Portfolio
      • 14.3.5.3. Financial Overview
      • 14.3.5.4. SWOT Analysis
      • 14.3.5.5. Strategic Overview
    • 14.3.6. Sanofi S.A.
      • 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.6.2. Product Portfolio
      • 14.3.6.3. Financial Overview
      • 14.3.6.4. SWOT Analysis
      • 14.3.6.5. Strategic Overview
    • 14.3.7. Helsinn Holding S.A.
      • 14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.7.2. Product Portfolio
      • 14.3.7.3. Financial Overview
      • 14.3.7.4. SWOT Analysis
      • 14.3.7.5. Strategic Overview
    • 14.3.8. Eisai Corporation
      • 14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.8.2. Product Portfolio
      • 14.3.8.3. Financial Overview
      • 14.3.8.4. SWOT Analysis
      • 14.3.8.5. Strategic Overview
    • 14.3.9. GlaxoSmithKline Corporation
      • 14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.9.2. Product Portfolio
      • 14.3.9.3. Financial Overview
      • 14.3.9.4. SWOT Analysis
      • 14.3.9.5. Strategic Overview
    • 14.3.10. Merck and Co.
      • 14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.10.2. Product Portfolio
      • 14.3.10.3. Financial Overview
      • 14.3.10.4. SWOT Analysis
      • 14.3.10.5. Strategic Overview